Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)

NCT05600062 | Active Not Recruiting

• 1 other identifier: 288749
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

Acute Respiratory Distress Syndrome (ARDS) is a severe type of lung injury that affects 10% of patients admitted to Intensive Care Units worldwide, with an unacceptably high mortality of up to 48% in those with the most severe form of the condition. It is a complex and poorly understood syndrome that results in progressive failure of the lungs. Crucially, the inflamed lungs allow fluid to leak from the circulation into the airspace, so that patients' lungs fill with fluid - "drowning from the inside". As this condition progresses, the patient typically requires increasing amounts of oxygen and eventually, support from a ventilator. To date, there are no effective treatments for ARDS that can limit, stop or repair this process. This research study is aiming to look at a naturally occurring substance produced by blood vessels, C-type natriuretic peptide (CNP). The investigators have evidence suggesting that CNP plays a role in maintaining the barrier provided by blood vessels that stops fluid leaking out into tissues. This is based on various studies done on CNP by the investigators research group that have established its widespread role in maintaining cells that line blood vessels and play a vital role in lungs' barrier function: the endothelium. CNP is broken down in part by an enzyme called Neutral endopeptidase and therefore, drugs that inhibit this enzyme would result in increased CNP concentration and activity. If CNP does in fact strengthen the lungs' endothelial barrier, then this class of drug may benefit patients with ARDS. The aim of this experimental medicine study is to assess the effect of using the licensed NEP inhibitor Racecadotril, in a well-established, safe model of inflammation-induced skin blisters in healthy human volunteers to determine primarily whether the fluid accumulation i.e. leak, in these blisters is reduced by treatment with this drug.

Conditions

Acute Respiratory Distress Syndrome

Keywords

ARDS; endothelium; CNP; Acute lung injury

Outcome Measures

Primary Outcomes (2)

• Powered unpaired inter-patient comparison of change in blister fluid volume following Racecadotril or placebo administration.

  24 hours after application of cantharidin

• Powered paired intra-patient comparison of change in blister fluid volume following Racecadotril or placebo admininstration.

  24 hours after application of cantharidin

Secondary Outcomes (5)

• Powered comparison of sex differences in change in blister volume following Racecadotril or placebo administration.

  End of study

• Difference in concentration of blister fluid cytokines; specifically Interleukin (IL) -1β, IL-6, IL-8, IL-10, CXCL1, CXCL2, CCL5 and CCL2 in volunteers receiving Racecadotril compared to placebo.

  24 hours after application of cantharidin

• Comparison of change in blister fluid leukocyte count following Racecadotril or placebo administration

  24 hours after application of cantharidin

• Comparison of change in pro and anti-inflammatory mediators from blister fluid following Racecadotril or placebo administration

  24 hours after application of cantharidin

• Comparison of change in plasma cGMP following oral Racecadotril or placebo administration

  24 hours after application of cantharidin

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Placebo tablet to be taken three times a day for three days

Drug: Placebo

Racecadotril

EXPERIMENTAL

Racecadotril 100 milligrams (mg) three times a day for three days

Drug: Racecadotril 100 milligram (MG) Oral Capsule

Interventions

Racecadotril 100 milligram (MG) Oral Capsule DRUG

Licensed NEP inhibitor

Also known as: Tiorfan

Racecadotril

Placebo DRUG

Placebo capsule

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Gender Eligibility Details: Equal number of males and females
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male and female volunteers
• BMI of 18-40 kg/m2
• Aged 18-45
• Volunteers who are willing to sign the consent form

You may not qualify if:

• Healthy subjects unwilling to consent
• Smokers
• Known sensitivity to Racecadotril
• History of any serious illnesses, including recent infections or trauma
• A personal history of keloid scarring, or a family history of keloid scarring in a first degree relative with similar skin pigmentation
• Subjects taking systemic medication (other than the oral contraceptive pill)
• Subjects who are pregnant or any possibility that a subject may be pregnant, unless in the latter case a pregnancy test is performed with a negative result
• Women who are breastfeeding
• Subjects with recent or current antibiotic use
• Subjects with a history of skins conditions.
• Subjects with a history of allergic reaction to any topical application or history of angioedema
• Subjects with any history of a blood-borne infectious disease such Hepatitis B or C virus, or HIV.

Sponsors & Collaborators

• Medical Research Council: collaborator
• Queen Mary University of London: lead

Study Sites (1)

William Harvey Research Institute- Heart Centre

London, United Kingdom

Location

MeSH Terms

Conditions

Respiratory Distress Syndrome; Acute Lung Injury

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Respiration Disorders; Lung Injury

Study Officials

• Adrian Hobbs

  Queen Mary University London

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 3, 2022
• First Posted: October 31, 2022
• Study Start: March 21, 2023
• Primary Completion: February 1, 2026
• Study Completion: June 15, 2026
• Last Updated: May 6, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: 6 months after publication
• Access Criteria: Access requests can be made to the investigators by email

Locations

GB (1)